Johnson & Johnson (JNJ) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$267.20

Open

$266.81

Day range

$266.30 – $268.65

Volume

4.9M

About Johnson & Johnson

Latest JNJ news

• This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
  MarketWatch · Sep 16, 2026

  Gargi Pal Chaudhuri, a strategist at BlackRock, has voiced her opposition to a potential interest rate hike by the Federal Reserve, emphasizing the need for a more cautious approach to monetary policy. Chaudhuri argues that raising rates could stifle economic growth, particularly in sectors that are still recovering from the pandemic. Instead, she advocates for investors to maintain their positions in the artificial intelligence sector, which has shown robust growth potential, while also diversifying into themes such as quality investments and healthcare. Chaudhuri's recommendations come at a time when market participants are weighing the implications of the Fed's monetary policy on various asset classes. By focusing on quality and healthcare, she suggests that investors can mitigate risks associated with economic uncertainty, particularly as inflationary pressures continue to influence market dynamics. These sectors are often seen as more resilient during economic downturns, providing a buffer against volatility. As the market anticipates the Fed's next move, Chaudhuri's insights may resonate with investors looking for stability amid fluctuating interest rates. Her emphasis on artificial intelligence aligns with broader trends in technology and innovation, which are expected to drive future growth. Overall, her recommendations reflect a strategic approach that balances growth opportunities with risk management in an uncertain economic landscape.

• KKR (KKR) Dropped, So What Is Driving Attention Now?
  Private Equity · Sep 16, 2026

  KKR & Co. Inc. has seen a notable decline in its stock price, prompting investors and analysts to reassess the firm's market position and future prospects. The drop comes amid a broader market volatility influenced by rising interest rates and economic uncertainty, which have particularly impacted private equity firms reliant on leveraged buyouts. As KKR navigates these challenges, attention is shifting towards its strategic responses, including potential asset sales and adjustments in investment strategies. Market analysts are closely monitoring KKR's portfolio performance, especially in sectors that have been hit hardest by economic headwinds. The firm has historically focused on sectors such as technology and healthcare, which may offer resilience in turbulent times. However, with rising costs and tightening credit conditions, KKR's ability to generate returns could be tested. Investors are also looking for insights into KKR's fundraising capabilities in the current environment, as the firm's ability to attract capital will be crucial for maintaining its competitive edge. In light of these developments, KKR's management is expected to provide clarity on its outlook during upcoming earnings calls. The firm's response to current market conditions will be pivotal in shaping investor sentiment and determining its stock trajectory in the near term. As KKR adapts to the evolving landscape, the implications for its valuation and market positioning will be closely scrutinized by both institutional and retail investors alike.

• IPEM 2026: M&A & Debt Joint Views - Natixis Corporate & Investment Banking
  IPO & M&A · Sep 15, 2026

  Natixis Corporate & Investment Banking has released its joint views on mergers and acquisitions (M&A) and debt markets in anticipation of the IPEM 2026 conference. The report highlights a cautious optimism regarding the M&A landscape, driven by a potential resurgence in deal-making activity as companies seek growth opportunities amid a recovering global economy. Key sectors expected to lead this activity include technology, healthcare, and renewable energy, as firms aim to capitalize on evolving market dynamics and consumer demands. In the debt markets, Natixis emphasizes the importance of interest rate trends and inflationary pressures, which could influence financing conditions for M&A transactions. The report suggests that while high interest rates may pose challenges, they could also lead to more strategic and disciplined deal-making as companies prioritize financial stability. Market participants are advised to closely monitor these developments, as they will likely shape the competitive landscape for both acquisitions and financing options in the coming years. Overall, the insights from Natixis underscore a pivotal moment for corporate strategy, with M&A activity poised to play a critical role in shaping the future of various industries.

• Trump Administration Moves to Integrate A.I. Into Medical Care Despite Concerns
  NYT Business · Sep 14, 2026

  The Trump administration is moving aggressively to weave artificial intelligence into the American health care system, pressing federal health agencies, hospitals, and insurers to adopt AI tools for clinical care, administrative work, and drug development even as patient advocates and some medical experts warn the technology is being deployed faster than safeguards can be built. The effort spans the Department of Health and Human Services, the Centers for Medicare and Medicaid Services, and the Food and Drug Administration, and aligns with the White House's broader deregulatory approach to AI, which has emphasized rapid adoption and rolled back guardrails established under the previous administration. Under the push, health officials have courted major technology companies to modernize patient data systems and develop AI-powered tools, while regulators have signaled a lighter touch on AI-enabled medical devices and software. Proponents within the administration argue that AI could ease physician burnout, cut administrative costs, accelerate drug discovery, and help address rural shortages of medical specialists. Critics, including some Democratic lawmakers, patient safety groups, and physicians, counter that the absence of rigorous validation standards raises the risk of biased algorithms, misdiagnoses, and privacy breaches involving sensitive health data. Lawmakers have also scrutinized insurers' use of AI in claims processing, amid lawsuits alleging algorithms were used to improperly cut off coverage for Medicare Advantage patients. For markets, the policy shift is a meaningful tailwind for the fast-growing health AI sector. Companies developing clinical AI, ambient documentation tools, and AI-driven drug discovery platforms stand to benefit from friendlier regulation and federal encouragement, while electronic health record vendors and cloud providers are positioning to capture demand for AI-ready data infrastructure. Investors are watching for concrete regulatory clarity from the FDA on AI device approvals and from CMS on reimbursement, which would determine how quickly adoption translates into revenue. Still, analysts caution that execution risk is high. A backlash over patient harm, data privacy, or denied claims could trigger congressional intervention and new liability exposure, and health systems remain wary of integrating tools that lack clear clinical evidence. The coming months will test whether the administration can scale AI in medicine quickly enough to satisfy its innovation agenda without provoking the safety and trust concerns that have shadowed the technology's entry into patient care.

• The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand
  Yahoo Finance · Sep 14, 2026

  The Cooper Companies is confronting a challenging stretch as demand growth in its core contact lens business decelerates, weighing on the near-term outlook for the medical device maker. CooperVision, which generates roughly 80 percent of the company's revenue, has benefited in recent years from a steady post-pandemic recovery and strong uptake of its daily disposable and myopia-control products. That momentum has cooled as the overall contact lens market shifts from the high-single-digit growth rates of the recovery period toward a more modest low-to-mid single-digit pace, leaving Cooper with less tailwind to offset competitive and macroeconomic pressures. Several factors are behind the slowdown. Consumers have grown more discretionary in their healthcare spending, and some eyecare practitioners and retailers have worked down inventory built up during supply-constrained periods, creating a destocking drag on shipments. Competition has also intensified in the daily disposable segment, where rivals including Alcon, Johnson & Johnson, and Bausch + Lomb continue to launch new silicone hydrogel lenses, pressuring pricing and market share. Even MiSight, Cooper's FDA-approved lens for slowing myopia progression in children, which had been a standout growth driver, has shown signs of more measured adoption as the company scales its salesforce and expands internationally. For investors, the deceleration raises questions about whether Cooper can sustain the premium valuation it has historically commanded as a consistent compounder in medtech. Shares have lagged at times when guidance has been trimmed, and any further softness in CooperVision's organic growth or margins could prompt analysts to lower estimates for the coming fiscal year. Peers reporting similar trends in vision care suggest the slowdown is largely a market-level phenomenon rather than a company-specific stumble, but that distinction offers limited comfort in the near term. Longer term, the structural case for contact lenses remains intact, supported by rising myopia prevalence, increased screen time, and aging populations, while CooperSurgical's fertility business offers a second growth engine if in-vitro fertilization volumes recover. Upcoming quarterly results and management commentary on fiscal-year guidance will be key catalysts, with investors looking for evidence that new product cycles, such as expanded MyDay offerings, can reaccelerate growth and stabilize sentiment around the stock.

• Vital Signs: Novartis' mounting M&A headaches
  IPO & M&A · Sep 13, 2026

  Novartis is facing increasing challenges in its mergers and acquisitions (M&A) strategy, as the pharmaceutical giant grapples with regulatory scrutiny and integration issues from recent deals. The company's attempts to bolster its pipeline through acquisitions have been met with skepticism from investors, particularly in light of the complexities involved in assimilating new assets and aligning them with its existing operations. This has raised concerns about the potential for value dilution and the effectiveness of Novartis' long-term growth strategy. Market analysts are closely monitoring Novartis' stock performance in response to these challenges. The company's shares have shown volatility, reflecting investor apprehension regarding its ability to successfully navigate the M&A landscape. Furthermore, the broader pharmaceutical sector is experiencing heightened competition and regulatory pressures, which could exacerbate Novartis' difficulties in executing future transactions. As the company seeks to reassure stakeholders, it may need to adopt a more cautious approach to M&A, focusing on organic growth and innovation rather than aggressive acquisitions.

• J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
  Yahoo Finance · Sep 12, 2026

  Johnson & Johnson is reportedly in negotiations to sell its DePuy Synthes unit, which specializes in hips and knees, to Apollo Global Management for approximately $20 billion. This move aligns with J&J's strategy to streamline its operations and concentrate on higher-growth segments within its portfolio. The divestiture of the DePuy Synthes business, a significant player in the orthopedic device market, reflects the company's ongoing efforts to enhance profitability and shareholder value. The potential sale comes at a time when the orthopedic market is experiencing shifts due to advancements in technology and changing patient demographics. If the deal proceeds, it could have substantial implications for both companies. For J&J, the divestiture would provide a substantial influx of capital that could be reinvested in more lucrative areas such as pharmaceuticals and consumer health products. For Apollo, acquiring DePuy Synthes could strengthen its position in the healthcare sector, allowing it to capitalize on the growing demand for orthopedic solutions. As the talks progress, market analysts will be closely monitoring the impact on J&J's stock performance and Apollo's investment strategy in the healthcare landscape.

• Apollo Global in talks to acquire J&J's orthopedics unit, Bloomberg News reports
  Private Equity · Sep 11, 2026

  Apollo Global Management is reportedly in advanced negotiations to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, with a potential valuation nearing $20 billion. This move aligns with J&J's strategy to streamline its operations by divesting non-core assets, a trend that has gained momentum as the company focuses on its pharmaceutical and consumer health divisions. The acquisition of DePuy Synthes would mark a significant expansion for Apollo in the healthcare sector, particularly in the lucrative orthopedic market, which has seen steady demand driven by an aging population and increasing rates of joint replacement surgeries. If the deal goes through, it could reshape the competitive landscape, potentially leading to further consolidation in the industry as other firms may seek to bolster their portfolios in response. Market analysts are closely monitoring the situation, as the outcome could influence stock prices for both companies. For Johnson & Johnson, a successful divestiture could provide capital for reinvestment in its core businesses, while Apollo's entry into the orthopedic space could enhance its investment strategy in healthcare, a sector that continues to attract significant investor interest.

• Triad experts weigh in on the Canadian and US trade war and how it could affect pharmaceuticals
  Geopolitics · Sep 11, 2026

  The ongoing trade tensions between Canada and the United States are raising concerns among industry experts regarding their potential impact on the pharmaceutical sector. As both nations grapple with tariffs and regulatory barriers, the implications for drug pricing, supply chains, and research collaboration are becoming increasingly pronounced. Experts warn that heightened trade disputes could lead to increased costs for pharmaceutical companies, which may ultimately be passed on to consumers in the form of higher drug prices. Moreover, the trade war could disrupt the intricate supply chains that underpin the pharmaceutical industry. Canada is a significant player in the production of active pharmaceutical ingredients (APIs) and generic drugs, and any restrictions on trade could hinder the availability of these essential components in the U.S. market. This disruption could lead to shortages and delays in drug production, further complicating the already challenging landscape of healthcare delivery. In light of these developments, pharmaceutical companies may need to reassess their strategies, potentially shifting production locations or increasing domestic sourcing to mitigate risks associated with trade volatility. Investors should remain vigilant, as the evolving trade dynamics could influence stock valuations within the sector, particularly for companies heavily reliant on cross-border trade. As the situation unfolds, the pharmaceutical industry will be closely monitoring policy changes and seeking ways to adapt to the shifting trade landscape.

• Here are the stocks to favor in the fourth quarter — and those you should avoid
  MarketWatch · Sep 10, 2026

  As the fourth quarter approaches, analysts are recommending a focus on large-cap stocks, which historically tend to outperform their smaller counterparts during this period. Factors contributing to this trend include increased institutional investment and a flight to safety as investors seek stability amid potential market volatility. Large-cap companies often have more robust balance sheets and greater access to capital, making them more resilient in uncertain economic conditions. Conversely, small-cap stocks may face headwinds as rising interest rates and inflation concerns persist. These companies typically rely more on domestic economic growth and may struggle to attract investment in a tightening monetary environment. Investors are advised to be cautious with small-cap equities, particularly those in sectors sensitive to consumer spending and economic downturns. In light of these dynamics, sectors such as technology and healthcare, which feature prominently among large-cap stocks, are expected to perform well. Conversely, investors may want to avoid small-cap stocks in cyclical industries like retail and consumer discretionary, where margins could be squeezed by ongoing economic pressures. As the year draws to a close, strategic positioning in large-cap equities could provide a buffer against potential market fluctuations.

All 102 articles in the app →

Index membership

• Dow Jones Industrial Average · Health Care
• S&P 500 · Health Care

Related Health Care stocks

• AMGNAmgen
• MRKMerck
• UNHUnitedHealth Group